Showing results (301-310 of 359) with videos related to

Sort By:
Pageof 36
Epilepsia|December 9, 2022
Spike patterns surrounding sleep and seizures localize the seizure-onset zone in focal epilepsyErin C Conrad, Andrew Y Revell, Adam S Greenblatt, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 12, 2017
Embryonic origin of primary colon cancer predicts survival in patients undergoing ablation for colorectal liver metastasesS Yamashita, B C Odisio, S Y Huang, et al.
The British Journal of Surgery|February 28, 2017
Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation statusB C Odisio, S Yamashita, S Y Huang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 18, 2002
Disposition and metabolic fate of atomoxetine hydrochloride: pharmacokinetics, metabolism, and excretion in the Fischer 344 rat and beagle dogEdward L Mattiuz, G Douglas Ponsler, Robert J Barbuch, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 13, 2020
Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE studyM Augustin, C E Kleyn, C Conrad, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 8, 2020
Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of HallopeauB Husson, C Barbe, S Hegazy, et al.
Neurology|September 23, 2025
Quantitative EEG Biomarkers in the Genetic Epilepsies and Associations With Neurologic OutcomesPeter D Galer, Jillian L McKee, Sarah M Ruggiero, et al.
Medrxiv : the Preprint Server for Health Sciences|October 17, 2024
Quantitative EEG Spectral Features Differentiate Genetic Epilepsies and Predict Neurologic OutcomesPeter D Galer, Jillian L McKee, Sarah M Ruggiero, et al.
Journal of Neuro-Oncology|June 27, 2008
Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastomaJ F de Groot, M R Gilbert, K Aldape, et al.
Pageof 36